Key Market Indicators
Icelander antirheumatic medicine sales are projected to reach $3.3 million by 2026. This is down 1.8% from 2021's estimated $3.9 million. Since 1994, the market has risen by an average of 1.4% each year. Iceland ranked 25th in 2021 with sales of $3.9 million. New Zealand came in ahead with sales of $3.85 million, followed by Germany, Spain and Canada at numbers 2, 3 and 4 respectively.
